摘要
目的:探讨益气通络安神方联合苯磺酸氨氯地平治疗高血压合并冠心病患者的临床疗效及安全性。方法:回顾性分析2022年5月至2024年5月河南建筑医院收治的95例高血压合并冠心病患者临床资料,根据治疗方案不同分为西药组(n=47)和中药联合组(n=48),均予以规范化对症支持治疗。在此基础上,西药组口服苯磺酸氨氯地平(2.5 mg•次^(-1),1次•d^(-1))治疗,中药联合组口服益气通络安神方(150 mL•次^(-1),早晚2次)联合苯磺酸氨氯地平治疗。治疗2 m后检测血压观察疗效。同时使用全自动生化分析仪检测总胆固醇(Total cholesterol,TC)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)水平,采用酶联免疫吸附法检测血清一氧化氮(Nitric oxide,NO)、血栓素A2(Thromboxane A2,TXA2)、内皮素-1(Endothelin-1,ET-1)、单核细胞趋化蛋白-1(Monocytes cell chemotactic protein-1,MCP-1)、可溶性血管黏附分子-1(Soluble vascular adhesion molecule-1,sVCAM-1)、单核细胞趋化蛋白-1诱导蛋白1(Monocyte chemotactic protein-1 induction protein 1,MCPIP1)水平,并记录治疗期间不良反应发生情况。结果:中药联合组总有效率为97.92%,高于西药组的82.98%(P<0.05);治疗2 m后,中药联合组收缩压、舒张压、TC、LDL-C水平低于西药组(P<0.05);治疗2 m后,中药联合组血清NO水平高于西药组,血清TXA2、ET-1、MCP-1、sVCAM-1、MCPIP1水平低于西药组(P<0.05);治疗期间,中药联合组不良反应发生率为8.33%,与西药组6.38%比较,无显著差异(P>0.05)。结论:益气通络安神方可有效抑制炎症反应,减轻血管内皮损伤,控制血压、血脂,减轻临床症状,提升临床疗效。
Objective:To investigate the clinical efficacy and safety of Yiqi Tongluo Anshen formula combined with amlodipine besylate in treating hypertension complicated with coronary heart disease patients.Methods:A retrospective analysis was conducted on the clinical data of 95 patients with hypertension complicated by coronary heart disease admitted to Henan Construction Hospital from May 2022 to May 2024.These patients were divided into the western medicine group(n=47)and the traditional Chinese medicine(TCM)combination group(n=48)based on different treatment regimens,both receiving standardized symptomatic supportive treatment.On this basis,the western medicine group was treated with oral amlodipine besylate(2.5 mg per dose,once daily),while the TCM combination group was treated with oral Yiqi Tongluo Anshen Formula(150 mL per dose,twice daily,morning and evening)in combination with amlodipine besylate.Blood pressure was measured after 2 months of treatment to observe the efficacy.At the same time,a fully automated biochemical analyzer was used to measure the levels of total cholesterol(TC)and low-density lipoprotein cholesterol(LDL-C),and enzyme-linked immunosorbent assay was used to detect the levels of serum nitric oxide(NO),thromboxane A2(TXA2),endothelin-1(ET-1),monocyte chemoattractant protein-1(MCP-1),soluble vascular adhesion molecule-1(sVCAM-1),and monocyte chemoattractant protein-1 induction protein 1(MCPIP1).The occurrence of adverse reactions during treatment was also recorded.Results:The total effective rate in the TCM combination group was 97.92%,which was higher than that in the western medicine group(82.98%)(P<0.05).After 2 months of treatment,the systolic and diastolic blood pressure,TC,and LDL-C levels in the TCM combination group were lower than those in the western medicine group(P<0.05).After 2 months of treatment,the serum NO level in the TCM combination group was higher than that in the western medicine group,while the serum levels of TXA2,ET-1,MCP-1,sVCAM-1,and MCPIP1 were lower than those in the western medicine group(P<0.05).During treatment,the incidence of adverse reactions in the TCM combination group was 8.33%,which was not significantly different from that in the western medicine group(6.38%)(P>0.05).Conclusion:Yiqi Tongluo Anshen Formula can effectively inhibit inflammatory reactions,reduce vascular endothelial damage,control blood pressure and blood lipids,alleviate clinical symptoms,and improve clinical efficacy.
作者
孔姗姗
董捷
方伟
Kong Shan-shan;Dong Jie;Fang Wei(Department of Pharmaceutical Equipment,Henan Architectural Hospital,Zhengzhou 450000,China;Department of Geriatric Endocrinology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Internal Medicine,Henan Architectural Hospital,Zhengzhou 450000,China)
基金
河南省医学科技攻关联合共建项目(编号:LHGJ20193670)。
关键词
高血压
冠心病
益气通络安神方
苯磺酸氨氯地平
临床疗效
Hypertension
Coronary heart disease
Yiqi Tongluo Anshen formula
Amlodipine besylate
Clinical efficacy
